- Home
- VIGL
as 11-21-2024 4:00pm EST
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 141.5M | IPO Year: | 2022 |
| Target Price: | $16.80 | AVG Volume (30 days): | 51.3K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.47 - $6.06 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Vigil Neuroscience Inc. News
VIGL Breaking Stock News: Dive into VIGL Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Vigil Neuroscience to Present at Upcoming Investor Conferences
GlobeNewswire
14 days ago
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update
Simply Wall St.
14 days ago
Vigil Neuroscience, Inc. (NASDAQ:VIGL) has caught the attention of institutional investors who hold a sizeable 41% stake
GlobeNewswire
16 days ago
Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference
Simply Wall St.
2 months ago
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?
Clinical Trials Arena
2 months ago
FDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trial
MT Newswires
2 months ago
Vigil Neuroscience Says FDA Lifts Partial Hold on Phase 1 Trial of Potential Alzheimer's Drug
GlobeNewswire
2 months ago
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
Compare VIGL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VIGL Vigil Neuroscience Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.